The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 999
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 91
Lü, S., Bao, M., Miao, S., Zhang, X., Jia, Q., Jing, S., Shan, T., Wu, X., & Liu, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.04 · Cited by 86
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study
Ferrannini, G., Manca, M. L., Magnoni, M., Andreotti, F., Andreini, D., Latini, R., Maseri, A., Maggioni, A. P., Ostroff, R. M., Williams, S. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1902 · Cited by 78
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 84
Pan, K., Hsu, Y., Chang, S., Chung, C., & Lin, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108604 · Cited by 80
Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2165 · Cited by 75
Crisafulli, A., Pagliaro, P., Roberto, S., Cugusi, L., Mercuro, G., Lazou, A., Beauloye, C., Bertrand, L., Hausenloy, D. J., Aragno, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082896 · Cited by 81
Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence
Amor, A. J., Gómez‐Guerrero, C., Ortega, E., Sala‐Vila, A., & Lázaro, I. (2020) · Antioxidants · doi:10.3390/antiox9121226 · Cited by 74
Shen, Y., Yu, J., Zhou, J., & Hu, G. (2024) · Journal of Medical Internet Research · doi:10.2196/59024 · Cited by 107
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Sasso, F. C., Simeon, V., Galiero, R., Caturano, A., Nicola, L. D., Chiodini, P., Rinaldi, L., Salvatore, T., Lettieri, M., Nevola, R., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01674-7 · Cited by 71
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes
Croyal, M., Saulnier, P., Aguesse, A., Gand, E., Ragot, S., Roussel, R., Halimi, J., Ducrocq, G., Cariou, B., Montaigne, D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa188 · Cited by 73
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V. R., Montoya, P. A., Colagiuri, S., Mohan, V., & Chan, J. C. N. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 78
Prioritising the primary prevention of heart failure
Khan, S. S., Berwanger, O., Fiuzat, M., McMurray, J. J. V., Narula, J., Prabhakaran, D., Sliwa, K. S., Tromp, J., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01393-5 · Cited by 81
Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Johnson, K. C., Pi-Sunyer, X., White, U., Olson, K. L., Bertoni, A. G., Kitzman, D. W., Berry, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050941 · Cited by 69
Anjana, R. M., Mohan, V., Rangarajan, S., Gerstein, H. C., Venkatesan, U., Sheridan, P., Dagenais, G. R., Lear, S. A., Teo, K. K., Karşıdağ, K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0886 · Cited by 68
Self-citationThe role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 73
Xie, B., Chen, S., Xu, Y., Han, W., Hu, R., Chen, M., Zhang, Y., & Ding, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.697442 · Cited by 72
Carbone, S., Billingsley, H., Canada, J. M., Bressi, E., Rotelli, B., Kadariya, D., Dixon, D. L., Markley, R., Trankle, C. R., Cooke, R. H., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3335 · Cited by 66
Sharma, A., & Verma, S. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 73
EUROASPIRE IV & V Investigators, Ferrannini, G., De Bacquer, D., Vynckier, P., De Backer, G., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Tuomilehto, J., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01233-6 · Cited by 54
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 73
Glucose variability: a new risk factor for cardiovascular disease
Belli, M., Bellia, A., Sergi, D., Barone, L., Lauro, D., & Barillà, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02097-w · Cited by 68
Kodama*, S., Fujihara, K., Horikawa, C., Sato, T., Iwanaga, M., Yamada, T., Kato, K., Watanabe, K., Shimano, H., Izumi, T., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12782 · Cited by 63
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events
Yang, Y., Peng, N., Chen, G., Wan, Q., Li, Y., Wang, G., Qin, Y., Luo, Z., Tang, X., Huo, Y., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01447-2 · Cited by 74
Andary, R., Fan, W., & Wong, N. D. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.035 · Cited by 63
Shen, Y., Zhou, J., Shi, L., Nauman, E., Katzmarzyk, P. T., Price‐Haywood, E. G., Horswell, R. L., Bazzano, A. N., Nigam, S., & Hu, G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14201 · Cited by 61
SGLT-2 inhibitors as cardio-renal protective agents
Caruso, I., & Giorgino, F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154937 · Cited by 62
Chen, L., Yin, X., Zhao, Y., Chen, H., Tan, T., Yao, P., & Tang, Y. (2022) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2022-219142 · Cited by 58
Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction
Baviera, M., Genovese, S., Colacioppo, P., Cosentino, N., Foresta, A., Tettamanti, M., Fortino, I., Roncaglioni, M. C., & Marenzi, G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01655-w · Cited by 62
Ghouse, J., Isaksen, J. L., Skov, M. W., Lind, B., Svendsen, J. H., Kanters, J. K., OLESEN, M. S., Holst, A. G., & Nielsen, J. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13891 · Cited by 70
Birkeland, K. I., Bodegård, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14189 · Cited by 56
Sarría‐Santamera, A., Orazumbekova, B., Maulenkul, T., Gaipov, A., & Atageldiyeva, K. K. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249523 · Cited by 60
van Gennip, A. C. E., Stehouwer, C. D. A., van Boxtel, M. P. J., Verhey, F. R. J., Koster, A., Kroon, A. A., Köhler, S., van Greevenbroek, M. M. J., Wesselius, A., Eussen, S. J. P. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0149 · Cited by 58
Patoulias, D., Papadopoulos, C. E., Stavropoulos, K., Zografou, I., Doumas, M. N., & Karagiannis, A. I. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13831 · Cited by 59
Şahin, İ., Bakıner, O., Demir, T., Sari, R., & Atmaca, A. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01612-8 · Cited by 66
Rhee, E. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.85 · Cited by 56
Geng, T., Xu, W., Gao, H., Zhang, J., Zou, J., Wang, K., Li, J., Guo, L., Wang, G., Chen, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.041 · Cited by 57
Read, S. H., Fischbacher, C., Colhoun, H. M., Gašević, D., Kerssens, J. J., McAllister, D., Sattar, N. A., & Wild, S. H. (2019) · Diabetologia · doi:10.1007/s00125-018-4796-7 · Cited by 58
Self-citationFan, W., Song, Y., Inzucchi, S. E., Sperling, L. S., Cannon, C. P., Arnold, S. V., Kosiborod, M., & Wong, N. D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13625 · Cited by 58
Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction
Schmitt, V. H., Hobohm, L., Münzel, T. F., Wenzel, P., Gori, T., & Keller, K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.003 · Cited by 59
Mohammadi, S., Hajhashemy, Z., & Saneei, P. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1926220 · Cited by 56
Nelson, A. J., Peterson, E. D., & Pagidipati, N. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.001 · Cited by 53
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 54
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 57
Andréasson, K., Edqvist, J., Adiels, M., Bjorck, L. M., Lindgren, M., Sattar, N. A., Lind, M., Åberg, M., & Rosengren, A. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101356 · Cited by 54
Self-citationAhmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2024) · Communications Medicine · doi:10.1038/s43856-023-00429-z · Cited by 70
The role of melatonin in targeting cell signaling pathways in neurodegeneration
Shukla, M., Chinchalongporn, V., Govitrapong, P., & Reiter, R. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14005 · Cited by 53
Salah, H. M., Sharma, T., & Mehta, J. L. (2020) · Cureus · doi:10.7759/cureus.10837 · Cited by 53
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 54
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 60
Heart failure and diabetes: Understanding the bidirectional relationship
Elendu, C., Amaechi, D. C., Elendu, T. C., Ashna, M., Ross-Comptis, J., Ansong, S. O., Egbunu, E. O., Okafor, G. C., Jingwa, K. A., Akintunde, A. A., et al. (2023) · Medicine · doi:10.1097/md.0000000000034906 · Cited by 51
Wang, B., Fu, Y., Tan, X. W., Wang, N., Qi, L., & Lu, Y. (2024) · BMC Medicine · doi:10.1186/s12916-024-03343-w · Cited by 59
Ceriello, A., de Valk, H. W., Guerci, B., Haak, T., Owens, D. R., Canobbio, M., Fritzen, K., Stautner, C., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108053 · Cited by 50
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective
Rocca, B., & Patrono, C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108008 · Cited by 48
Rajlic, S., Treede, H., Münzel, T. F., Daiber, A., & Duerr, G. D. (2023) · Cells · doi:10.3390/cells12040583 · Cited by 51
Li, R., Liu, Y., Shan, Y., Gao, L., Wang, F., & Qiu, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3206542 · Cited by 47
Luo, J., Schmaus, J., Cui, M., Hörterer, E., Wilk, U., Höhn, M., Däther, M., Berger, S., Benli‐Hoppe, T., Peng, L., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.022 · Cited by 47
Zhong, Y., Zhou, L., Liu, X., Deng, L., Wu, R.-N., Xia, Z., Mo, G., Zhang, L., Liu, Z., & Tang, J. Y. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00429-3 · Cited by 50
Arroyave, F., Montaño, D., & Lizcano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228685 · Cited by 52
Seo, D. Y., Ko, J. R., Jang, J. E., Kim, T. N., Youm, J. B., Kwak, H., Bae, J. H., Kim, A. H., Ko, K. S., Rhee, B. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246284 · Cited by 46
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 47
From NAFLD to MAFLD: Nurse and allied health perspective
Clayton, M., Fabrellas, N., Luo, J., Alghamdi, M., Hafez, A., Qadiri, T. A., Owise, N., & Attia, D. I. (2021) · Liver International · doi:10.1111/liv.14788 · Cited by 46
Ceriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Frigé, C., Cosmo, S. D., Bartolo, P. D., Cianni, G. D., Fioretto, P., Giorda, C. B., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100666 · Cited by 53
Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts
Арманович, А. А., Fogacci, F., Вачиковна, П. Н., Kakrurskiy, L., Коган, Е. А., Urazova, O. I., Kobalava, Z. D., Михалева, Л. М., Vandysheva, R. A., Zarina, G., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102052 · Cited by 52
Lu, L., Ma, J., Yang, L., Shao, Y., Xiong, X., Duan, W., Gao, E., Yang, Q., Chen, S., Yang, J. Z., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.757068 · Cited by 46
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J. P., Vasques‐Nóvoa, F., Ferrão, D., Saraiva, F. A., Falcão‐Pires, I., Neves, J. S., Sharma, A., Rossignol, P., Zannad, F. M., & Leite-Moreira, A. F. (2022) · Diabetes Care · doi:10.2337/dc21-1977 · Cited by 45
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 43
Self-citationWu, S., Lu, D., Gajendran, B., Hu, Q., Zhang, J., Wang, S., Han, M., Xu, Y., & Shen, X. (2023) · Phytotherapy Research · doi:10.1002/ptr.7831 · Cited by 45
Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure
Sinha, A., Ning, H., Carnethon, M. R., Allen, N. B., Wilkins, J. T., Lloyd‐Jones, D. M., & Khan, S. S. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008113 · Cited by 43
Sharma, A., Vaduganathan, M., Ferreira, J. P., Liu, Y., Bakris, G. L., Cannon, C. P., White, W. B., & Zannad, F. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012797 · Cited by 40
the DARWIN-T2D Network of the Italian Diabetes Society, Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01164-8 · Cited by 47
Akasaka, H., Sugimoto, K., Shintani, A., Taniuchi, S., Yamamoto, K. I., Iwakura, K., Okamura, A., Takiuchi, S., Fukuda, M., Kamide, K., et al. (2022) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14363 · Cited by 41
Qian, W., Cai, X., Qian, Q., Zhuang, Q., Yang, W., Zhang, X., & Zhao, L. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207774 · Cited by 42
Sha, Y.-H., Huang, X., Ke, P., Wang, B., Yuan, H., Yuan, W., Wang, Y., Zhu, X., & Yan, Y. (2020) · Obesity Surgery · doi:10.1007/s11695-019-04378-2 · Cited by 44
Jiang, Z., Fu, L., Xu, Y., Hu, X., Yang, H., Zhang, Y., Luo, H., Gan, S., Tao, L., Liang, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63498-3 · Cited by 42
Coles, B., Zaccardi, F., Ling, S., Davies, M. J., Samani, N. J., & Khunti, K. K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13464 · Cited by 41
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., Rozenberg, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1744 · Cited by 42
Self-citationAssociation Between Excess Leisure Sedentary Time and Risk of Stroke in Young Individuals
Joundi, R. A., Patten, S. B., Williams, J. V. A., & Smith, E. E. (2021) · Stroke · doi:10.1161/strokeaha.121.034985 · Cited by 43
Zabala, A., Darsalia, V., Holzmann, M. J., Franzén, S., Svensson, A., Eliasson, B., Patrone, C., Nyström, T., & Jonsson, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13885 · Cited by 41
Self-citationZhang, D., He, Y., Ye, X., Cai, Y., Xu, J., Zhang, L., Li, M., Liu, H., Wang, S., & Xia, Z. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13235 · Cited by 41
Regassa, L. D., Tola, A., & Ayele, Y. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.532719 · Cited by 41
Artime, E., Romera, I., Díaz‐Cerezo, S., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01060-8 · Cited by 45
Silva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., de la Torre-Saldaña, V., León-García, E., Serna-Alvarado, J., GUZMAN-OLVERA, E. B., Cabrera, D., Gay, J. G., & Prada, D. (2020) · International Journal for Equity in Health · doi:10.1186/s12939-020-01188-2 · Cited by 43
The residual cardiorenal risk in type 2 diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01229-2 · Cited by 40
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 40
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Giugliano, D., Scappaticcio, L., Longo, M., Bellastella, G., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01400-9 · Cited by 44
Myocardial glucotoxicity: Mechanisms and potential therapeutic targets
Battault, S., Renguet, E., Steenbergen, A. V., Horman, S., Beauloye, C., & Bertrand, L. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.06.006 · Cited by 43
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
Lind, V., Hammar, N., Lundman, P., Friberg, L., Talbäck, M., Walldius, G., & Norhammar, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01422-3 · Cited by 43
Segar, M. W., Patel, K. V., Hellkamp, A. S., Vaduganathan, M., Lokhnygina, Y. V., Green, J. B., Wan, S., Kolkailah, A. A., Holman, R. R., Peterson, E. D., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024094 · Cited by 38
Self-citationAroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 40
Wu, H., Lau, E. S. H., Yang, A., Zhang, X., Fan, B., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004173 · Cited by 40
Patel, K. V., Segar, M. W., Klonoff, D. C., Khan, M. S., Usman, M. S., Lam, C. S. P., Verma, S., DeFilippis, A. P., Nasir, K., Bakker, S. J. L., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067530 · Cited by 38
Lim, L.-L., Lau, E. S. H., Fu, A. W. C., Ray, S., Hung, Y.-J., Tan, A. T. B., Chamnan, P., Sheu, W. H. H., Chawla, M. S., Chia, Y.-C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.7557 · Cited by 37
Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes
Rawshani, A., Sattar, N. A., McGuire, D. K., Wallström, O., Smith, U., Borén, J., Bergström, G. M. L., Ömerovic, E., Rosengren, A., Eliasson, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058072 · Cited by 44
Self-citation
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
